Patents by Inventor Samir Undevia

Samir Undevia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS RELATING TO PHARMACOGENETICS OF DIFFERENT GENE VARIANTS IN THE CONTEXT OF IRINOTECAN-BASED THERAPIES
    Publication number: 20090247475
    Abstract: The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient.
    Type: Application
    Filed: May 12, 2006
    Publication date: October 1, 2009
    Applicants: The Regents of the University of California, The University of Chicago
    Inventors: Mark J. Ratain, Federico Innocenti, Deanna L. Kroetz, Samir Undevia, Tan D. Nguyen, Wanqing Liu
  • METHODS AND COMPOSITIONS RELATING TO THE PHARMACOGENETICS OF DIFFERENT GENE VARIANTS
    Publication number: 20090017452
    Abstract: The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient.
    Type: Application
    Filed: March 7, 2005
    Publication date: January 15, 2009
    Applicant: UNIVERSITY OF CHICAGO
    Inventors: Mark J. Ratain, Federico Innoceti, Deanna L. Kroetz, Samir Undevia, Tan D. Nguyen, Wanqing Liu